Navigation Links
Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients
Date:9/17/2008

-CSF and interferon-alpha-2b.

About the Clinical Trial

The randomized, open-label trial involves 120 participants at 23 centers across the United States and Canada. Stage IIIc, IVa and IVb melanoma patients with at least one measurable lesion and a life expectancy of at least six months will be included in the study. Participants will be randomized to one of two study groups. The first group will receive vaccine treatment consisting of a series of ALVAC and GM-CSF injections, followed by administration of interferon. The second group will receive administration of interferon alone.

The study is designed with the primary objective of progression-free survival (tumor stabilization) and the secondary objective of evaluation of safety, other efficacy endpoints (response rates), and the ability of the treatment regimen to induce an immune response.

The first cycle of vaccine treatment is conducted for a period of 16-weeks. If there is no evidence of disease progression during the first cycle, vaccine treatment is extended to a second 16 week cycle of treatment. In the study, patients in Group 2 whose disease has progressed during the first treatment cycle may be offered the vaccine regimen as the next cycle of treatment.

About Melanoma

Melanoma is the most serious form of skin cancer, accounting for 80 percent of all skin cancer deaths. Incidence and mortality rates for melanoma are rising faster than those for any other cancer. According to the American Cancer Society and Canadian Cancer Society, this year nearly 65,000 people in North America will be diagnosed with melanoma and more than 9,000 will die from the disease. By the year 2010, it is estimated that one in 50 people will have been diagnosed with melanoma. Standard treatments have minimal effect on survival, and sometimes cause significant toxicity.

About Therapeutic Cancer Vaccines

Therapeutic cancer vaccines represent an emerging, experimental type of
'/>"/>

SOURCE sanofi pasteur
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate ... hold a conference call on Thursday, August 14, 2014, at ... quarter ended June 30, 2014. Financial results will be issued ... Vermillion,s Chairman, President and CEO James LaFrance will ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. ...
(Date:7/31/2014)... YORK , July 31, 2014 TB ... better, faster and affordable treatments for tuberculosis (TB), announced ... Vice President, Market Access. Ms. Robertson joins the organization ... company,s business in Sub-Saharan Africa and Eastern ... oversee the TB Alliance,s efforts to ensure beneficial new ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... the eighth annual Prix Galien USA ... biomedical industry,s highest accolade and recognizes the technical, scientific ... and devices. This year brings the highest ... Galien USA . Nominees include biomedical ...
Breaking Medicine Technology:Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... ... C Clarification of Oncogenic Pathways ... Potential Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology ... Meeting of the European,Association for the Study of the Liver (EASL), experts reported advances ...
... YORK, April 24 PulmoBioTech Inc. (OTC,Bulletin Board: PLMO) ... the areas that it will be investigating as part ... are:, 1. Efficacy Binding Studies 2. ... 4. Pyrogenicity 5. Immunological Testing 6. ...
Cached Medicine Technology:Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4PulmoBioTech Announces Details of Its Regulatory Approval Experiments 2PulmoBioTech Announces Details of Its Regulatory Approval Experiments 3
(Date:7/31/2014)... have asthma, you may have an asthma action plan with ... to changes and understand when symptoms are getting worse and ... doing well, yellow means your asthma has worsened and action ... guidelines are now available to help your allergist steer you ... from the red zone. , "Management of acute loss of ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , ... East Horn Road in Lake Leelanau. Joining the Northern Loop ... is the 25th winery along the trail. The winery will ... events, making its trail event debut during the Harvest Stompede ... David and Faye Mathia opened the boutique winery in the ...
(Date:7/31/2014)... 2014 0-6 Pack Abs has finally been ... therapist expert Dr. James Vegher. Together they have launched ... relieve digestive issues, tone core muscles, improve posture, eliminate achy ... core exercises used to re-train the body in order to ... 0-6 Pack Abs review, Shane Michaels, a fitness ...
(Date:7/31/2014)... July 31, 2014 Adventist Health ... the U.S. including Florida Hospital Tampa, Florida Hospital ... Florida Hospital North Pinellas, Florida Hospital Wesley Chapel, ... Sebring, Florida Hospital Heartland Medical Center Lake Placid ... Networks list of Most Wired Hospitals and Health ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure ... Doctors will be able to verify their patients before ... which guarantees their authenticity. This will help prospective ... receive information that has been verified to come from ... Cosmetic Town to filter out fake patients who leave ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... Venture," a one-day workshop about the basics of technology ... takes to launch a startup venture. Presentations ... intellectual property issues and business plans. Participants include Erica ... at Carnegie Mellon whose research focuses on the role ...
... 16, 2010Announcing the launch of the Liebert Mobile ... latest news, resources, press releases, research, and multimedia ... information across the biomedical, biotechnology, medicine, surgery, and ... is available with this free application. ...
... The ... ... its new Prodigy Count-a-dose™ April 1, a precise and safe syringe-filling device for the blind ... can easily measure and mix two insulins at one time. The device had been pulled ...
... A ... released today. This new concept protects consumers by enabling them to pay less, get more, and ... and legal problems relating to the construction. , ... (PRWEB) March 16, 2010 -- Stop Ripping Me Off! is the title of ...
... puts cost per life-year gained at about $66,200 ... agents for metastatic colon cancer improve patient survival but ... Emory University in Atlanta analyzed data from 4,665 patients, ... between 1995 and 2005. Compared to those who received ...
... bothered by treatment,s effects, study finds , TUESDAY, March ... enough radiation to shield patients from prostate cancer,s return ... as tricky as once thought, new research shows. , ... time. In fact, 10 years after treatment, prostate cancer ...
Cached Medicine News:Health News:Prodigy Re-Launches Syringe-Filling System for Blind and Low-Vision Diabetics 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 3Health News:Are New Chemo Treatments Cost-Effective? 2Health News:Prostate Cancer Radiation Side Effects May Subside With Time 2
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... agreement between Brook Brothers and Luxottica ... by lightweight materials and a slender ... the unique features of the style ... with classic style and affordable to ...
... Ray-Ban brand debuted in 1937 with the ... was added to Luxottica Group's brand portfolio ... show business celebrities since day one, Ray-Bans ... far the best-selling sunglasses in the world. ...
... Group has been manufacturing the Anne Klein ... Klein eyewear collections are designed for an ... wear Anne Klein eyewear identifies herself with ... refined career woman who is image-conscious and ...
Medicine Products: